BRPI0814957A2 - Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto. - Google Patents

Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.

Info

Publication number: BRPI0814957A2
Authority: BR; Brazil
Prior art keywords: compound; prophylaxy; disorder; disease; treatment
Prior art date: 2007-08-07

Application number

BRPI0814957-7A2A

Other languages

English (en)

Inventor

Atsushi Hasuoka

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-07

Filing date

2008-08-06

Publication date

2015-02-03

2008-08-06 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2015-02-03 Publication of BRPI0814957A2 publication Critical patent/BRPI0814957A2/pt

2019-12-03 Publication of BRPI0814957B1 publication Critical patent/BRPI0814957B1/pt

2021-05-25 Publication of BRPI0814957B8 publication Critical patent/BRPI0814957B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0814957A 2007-08-07 2008-08-06 composto, agente farmacêutico, e, uso do composto BRPI0814957B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2007205966		2007-08-07
JP2007299658		2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en)	2007-08-07	2008-08-06	Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (3)

Publication Number	Publication Date
BRPI0814957A2 true BRPI0814957A2 (pt)	2015-02-03
BRPI0814957B1 BRPI0814957B1 (pt)	2019-12-03
BRPI0814957B8 BRPI0814957B8 (pt)	2021-05-25

Family

ID=40329363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814957A BRPI0814957B8 (pt)	2007-08-07	2008-08-06	composto, agente farmacêutico, e, uso do composto

Country Status (35)

Country	Link
US (2)	US7834051B2 (pt)
EP (1)	EP2176220B1 (pt)
JP (1)	JP5292390B2 (pt)
KR (1)	KR20100049644A (pt)
CN (1)	CN101821235B (pt)
AR (1)	AR067823A1 (pt)
AU (1)	AU2008284662B2 (pt)
BR (1)	BRPI0814957B8 (pt)
CA (1)	CA2695852C (pt)
CL (1)	CL2008002313A1 (pt)
CO (1)	CO6160326A2 (pt)
CR (1)	CR11266A (pt)
CY (1)	CY1114067T1 (pt)
DK (1)	DK2176220T3 (pt)
DO (1)	DOP2010000053A (pt)
EA (1)	EA017429B1 (pt)
ES (1)	ES2406685T3 (pt)
GE (1)	GEP20125571B (pt)
HK (1)	HK1143972A1 (pt)
HR (1)	HRP20130374T1 (pt)
JO (1)	JO2864B1 (pt)
MA (1)	MA31639B1 (pt)
ME (1)	ME01579B (pt)
MX (1)	MX2010001484A (pt)
MY (1)	MY159910A (pt)
NZ (1)	NZ583624A (pt)
PE (1)	PE20090899A1 (pt)
PL (1)	PL2176220T3 (pt)
PT (1)	PT2176220E (pt)
RS (1)	RS52812B (pt)
SI (1)	SI2176220T1 (pt)
TN (1)	TN2010000062A1 (pt)
TW (1)	TWI418543B (pt)
WO (1)	WO2009020234A2 (pt)
ZA (1)	ZA201001289B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2176220T1 (sl) *	2007-08-07	2013-05-31	Takeda Pharmaceutical Company Limited	Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev
US8268872B2 (en)	2008-02-22	2012-09-18	Radius Health, Inc.	Selective androgen receptor modulators
JP5308458B2 (ja)	2008-02-22	2013-10-09	ラジウスヘルス，インコーポレイテッド	選択的アンドロゲン受容体調節物質
UY31736A (es) *	2008-03-26	2009-11-10	Takeda Pharmaceutical	Derivados sustituidos de pirazol y su uso
JP5964756B2 (ja)	2010-02-04	2016-08-03	ラジウスヘルス，インコーポレイテッド	選択的アンドロゲン受容体モジュレーター
PT2568806T (pt)	2010-05-12	2016-08-05	Radius Health Inc	Regimes terapêuticos
US8642632B2 (en)	2010-07-02	2014-02-04	Radius Health, Inc.	Selective androgen receptor modulators
BR112013007685B1 (pt)	2010-09-28	2021-11-09	Radius Pharmaceuticals, Inc	Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
EP2834216A1 (en) *	2012-04-04	2015-02-11	Catylix Inc.	Selective androgen receptor modulators
CN107184569A (zh)	2012-08-09	2017-09-22	迪纳米斯治疗公司	保持或改善对象健康、幸福和/或生理功能的方法
US9868905B2 (en)	2012-09-21	2018-01-16	Merck Patent Gmbh	Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es)	2014-03-28	2023-04-28	Univ Duke	Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
KR101597327B1 (ko)	2014-04-24	2016-02-24	동아에스티 주식회사	옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) *	2014-05-06	2016-04-20	成都安斯利生物医药有限公司	一种制备3,5-二氟-4-甲基苯硼酸的方法
CA3027563A1 (en)	2016-06-22	2017-12-28	Radius Health, Inc.	Ar+ breast cancer treatment methods
HRP20240923T1 (hr)	2017-01-05	2024-10-11	Radius Pharmaceuticals, Inc.	Polimorfni oblici rad1901-2hcl
MX2020013713A (es)	2018-07-04	2021-03-02	Radius Pharmaceuticals Inc	Formas polimorficas de rad1901-2hcl.
CN110204505B (zh) *	2019-05-31	2023-02-03	荆门医药工业技术研究院	(s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) *	2019-11-20	2023-01-19	Medshine Discovery Inc.	Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4141399A1 (de)	1991-12-16	1993-06-17	Bayer Ag	4-(substituierte)amino-3-arylpyrrolinon-derivate
CN1129581C (zh) *	1998-09-22	2003-12-03	山之内制药株式会社	氰基苯基衍生物
US6258833B1 (en)	1999-12-23	2001-07-10	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en)	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) *	2000-09-08	2002-03-27	Yamanouchi Pharmaceut Co Ltd	抗アンドロゲン剤
FR2817472B1 (fr)	2000-12-06	2003-01-03	Oreal	Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
CA2469340A1 (en)	2001-12-06	2003-06-19	Gtx Inc.	Treating muscle wasting with selective androgen receptor modulators
WO2003057669A1 (fr) *	2001-12-28	2003-07-17	Takeda Chemical Industries, Ltd.	Antagonistes du recepteur androgene
JP4316232B2 (ja)	2001-12-28	2009-08-19	武田薬品工業株式会社	アンドロゲン受容体拮抗剤
TW200407280A (en)	2002-06-17	2004-05-16	Univ Tennessee Res Foundation	N-bridged selective androgen receptor modulators and methods of use thereof
BR0313405A (pt)	2002-08-12	2005-07-12	Takeda Pharmaceutical	Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto
GB0402492D0 (en)	2004-02-04	2004-03-10	Pfizer Ltd	Pharmaceutically active compounds
WO2005090282A1 (en) *	2004-03-12	2005-09-29	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
MXPA06013115A (es)	2004-05-11	2007-02-28	Pfizer Prod Inc	Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
EP1756101A2 (en)	2004-05-17	2007-02-28	Acadia Pharmaceuticals Inc.	Androgen receptor modulators and method of treating disease using the same
CA2543827C (en)	2004-06-07	2010-03-09	James T. Dalton	Selective androgen receptor modulators and methods of use thereof
CA2594340C (en)	2005-01-10	2015-11-10	Acadia Pharmaceuticals Inc.	Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en)	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
ES2314922T3 (es)	2005-05-13	2009-03-16	Eli Lilly And Company	N-arilpirrolidinas sustituidas como moduladores selectivos del receptor de androgenos.
WO2007015567A1 (ja)	2005-08-01	2007-02-08	Takeda Pharmaceutical Company Limited	環状アミン化合物
US20090042857A1 (en) *	2006-02-20	2009-02-12	Masuo Yamaoka	Novel Pharmaceutical
CA2658098A1 (en)	2006-07-19	2008-01-24	Osurf	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
WO2008014311A2 (en) *	2006-07-26	2008-01-31	Novartis Ag	Inhibitors of undecaprenyl pyrophosphate synthase
WO2008066117A1 (fr)	2006-11-30	2008-06-05	Takeda Pharmaceutical Company Limited	Composé amine cyclique
SI2176220T1 (sl) *	2007-08-07	2013-05-31	Takeda Pharmaceutical Company Limited	Pirolidin-2-onski derivati kot modulatorji androgenskih receptorjev

2008
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en active Application Filing
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 RS RS20130235A patent/RS52812B/en unknown
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko active IP Right Grant
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 US US12/672,516 patent/US8420694B2/en active Active
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
2010
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
- 2010-10-19 HK HK10109899.1A patent/HK1143972A1/xx not_active IP Right Cessation
2013
- 2013-04-29 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown

Also Published As

Publication number	Publication date
RS52812B (en)	2013-10-31
CY1114067T1 (el)	2016-07-27
CN101821235A (zh)	2010-09-01
ES2406685T3 (es)	2013-06-07
JP5292390B2 (ja)	2013-09-18
US7834051B2 (en)	2010-11-16
AU2008284662B2 (en)	2013-07-25
US8420694B2 (en)	2013-04-16
AR067823A1 (es)	2009-10-21
ME01579B (me)	2014-09-20
US20110098336A1 (en)	2011-04-28
PL2176220T3 (pl)	2013-08-30
CA2695852C (en)	2017-01-03
EP2176220B1 (en)	2013-03-27
BRPI0814957B1 (pt)	2019-12-03
DK2176220T3 (da)	2013-06-10
CN101821235B (zh)	2012-11-14
TWI418543B (zh)	2013-12-11
EA017429B1 (ru)	2012-12-28
MY159910A (en)	2017-02-15
NZ583624A (en)	2012-06-29
TW200916439A (en)	2009-04-16
KR20100049644A (ko)	2010-05-12
GEP20125571B (en)	2012-07-10
EA201070246A1 (ru)	2010-08-30
US20090042967A1 (en)	2009-02-12
DOP2010000053A (es)	2010-07-15
BRPI0814957B8 (pt)	2021-05-25
MX2010001484A (es)	2010-03-04
MA31639B1 (fr)	2010-08-02
ZA201001289B (en)	2011-04-28
JO2864B1 (en)	2015-03-15
WO2009020234A3 (en)	2009-04-16
CA2695852A1 (en)	2009-02-12
CR11266A (es)	2010-03-22
PT2176220E (pt)	2013-04-09
EP2176220A2 (en)	2010-04-21
TN2010000062A1 (en)	2011-09-26
CO6160326A2 (es)	2010-05-20
HK1143972A1 (en)	2011-01-21
AU2008284662A1 (en)	2009-02-12
WO2009020234A2 (en)	2009-02-12
JP2010535704A (ja)	2010-11-25
CL2008002313A1 (es)	2009-05-15
HRP20130374T1 (en)	2013-05-31
PE20090899A1 (es)	2009-08-06
SI2176220T1 (sl)	2013-05-31

Publication	Publication Date	Title
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2008000691A1 (es)	2008-09-12	Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI1011220A2 (pt)	2016-03-15	composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0720169A2 (pt)	2013-12-24	Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-09	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-12-03	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-09-08	B15V	Prolongation of time limit allowed
2024-05-28	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-09-17	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2786 DE 28-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.